CHRM1
ENSG00000168539
Target class
GPCR
Chromosome
11
Approved drugs
35
Clinical candidates (approved and in development)
42
- Approved drugs
- 35
- Clinical candidates (approved and in development)
- 42
- Chemical probe available
- Yes
- Target name
- CHRM1
- Gene name
- Cholinergic receptor muscarinic 1
- Gene symbol
- CHRM1
- Protein name
- Muscarinic acetylcholine receptor M1
- Gene biotype
- Protein coding
- Gene family
- Cholinergic receptors muscarinic
- Target class
- GPCR
- Target type
- Human gene
- Tissues expressed in
- 14
- Highest tissue expression
- 55.18
- Tissue specificity (Gini)
- 0.835
- Tissue specificity (tau)
- 0.911
- KEGG gene identifiers
- hsa:1128
- Protein interaction confidence
- 0.828914
- Protein interaction partners
- 35
- R-HSA-390648
- R-HSA-416476
- End position
- 62921877
- Start position
- 62908679
- Chromosome
- 11
- Strand
- Reverse
- Cell membrane
- Multi-pass membrane protein. Postsynaptic cell membrane
- Multi-pass membrane protein.
- Tissue specificity (tau)
- 0.911015
- Expression inequality (Gini)
- 0.835254
Expression in transcripts per million
- Brain - Cortex
- 55.18
- Brain - Frontal Cortex (BA9)
- 52.43
- Brain - Nucleus accumbens (basal ganglia)
- 37.87
- Brain - Anterior cingulate cortex (BA24)
- 27.64
- Brain - Caudate (basal ganglia)
- 25.74
Expression in transcripts per million
- Brain - Cortex55.18
- Brain - Frontal Cortex (BA9)52.43
- Brain - Nucleus accumbens (basal ganglia)37.87
- Brain - Anterior cingulate cortex (BA24)27.64
- Brain - Caudate (basal ganglia)25.74
- Prostate25.64
- Brain - Putamen (basal ganglia)21.44
- Minor Salivary Gland18.81
- Brain - Hippocampus18.56
- Brain - Amygdala14.77
- Skin - Sun Exposed (Lower leg)4.18
- Skin - Not Sun Exposed (Suprapubic)3.14
- Lung2.17
- Brain - Hypothalamus1.46
- Colon - Sigmoid0.67
- Breast - Mammary Tissue0.67
- Colon - Transverse0.6
- Stomach0.6
- Brain - Substantia nigra0.49
- Small Intestine - Terminal Ileum0.4
- Brain - Spinal cord (cervical c-1)0.29
- Esophagus - Gastroesophageal Junction0.24
- Esophagus - Muscularis0.24
- Brain - Cerebellar Hemisphere0.2
- Brain - Cerebellum0.2
And 29 more, listed on the interactive page.
- GO:0007165
- GO:0007186
- GO:0007200
- GO:0007207
- GO:0007213
- GO:0007399
- GO:0043270
- GO:0060251
- GO:0005886
- GO:0016020
- GO:0004435
- GO:0005515
- GO:0016907
exhaustion
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: exhaustion
- nervous system
- respiratory
- liver
- cardiovascular
- gastrointestinal
PubMed 28216264gastrointestinal side effects
Effects
- Activation/Increase/Upregulation: general
Studies
- clinical: gastrointestinal side effects
- cardiovascular system
- nervous system
- gastrointestinal
Evidence sourceincreased gastric acid secretion
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased gastric acid secretion
- nervous system
- respiratory
- liver
- cardiovascular
- gastrointestinal
PubMed 28216264decreased gastric acid secretion
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased gastric acid secretion
- nervous system
- respiratory
- liver
- cardiovascular
- gastrointestinal
PubMed 28216264increased blood pressure
Effects
- Activation/Increase/Upregulation: general
Studies
- clinical: increased blood pressure
- cardiovascular system
- nervous system
- gastrointestinal
Evidence sourceabdominal cramps
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: abdominal cramps
- nervous system
- respiratory
- liver
- cardiovascular
- gastrointestinal
PubMed 28216264increased/decreased blood pressure
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased/decreased blood pressure
- nervous system
- respiratory
- liver
- cardiovascular
- gastrointestinal
PubMed 28216264decreased convulsions
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased convulsions
- nervous system
- respiratory
- liver
- cardiovascular
- gastrointestinal
PubMed 28216264increased body temperature
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased body temperature
- nervous system
- respiratory
- liver
- cardiovascular
- gastrointestinal
PubMed 28216264frothing
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: frothing
- nervous system
- respiratory
- liver
- cardiovascular
- gastrointestinal
PubMed 28216264increased memory
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased memory
- nervous system
- respiratory
- liver
- cardiovascular
- gastrointestinal
PubMed 28216264regulation of circadian rhythm
Effects
- Activation/Increase/Upregulation: general
Studies
- clinical: regulation of circadian rhythm
- cardiovascular system
- nervous system
- gastrointestinal
Evidence sourceliver failure
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: liver failure
- nervous system
- respiratory
- liver
- cardiovascular
- gastrointestinal
PubMed 28216264bronchorrhea
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: bronchorrhea
- nervous system
- respiratory
- liver
- cardiovascular
- gastrointestinal
PubMed 28216264increased heart rate
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased heart rate
- nervous system
- respiratory
- liver
- cardiovascular
- gastrointestinal
PubMed 28216264increased heart rate
Effects
- Activation/Increase/Upregulation: general
Studies
- clinical: increased heart rate
- cardiovascular system
- nervous system
- gastrointestinal
Evidence sourceblurred vision
- Inhibition/Decrease/Downregulation: acute
- Activation/Increase/Upregulation: acute
Studies
- preclinical: blurred vision
- nervous system
- respiratory
- liver
- cardiovascular
- gastrointestinal
PubMed 28216264increased convulsions
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased convulsions
- nervous system
- respiratory
- liver
- cardiovascular
- gastrointestinal
PubMed 28216264disruption of cognitive functions such as learning and memory
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- clinical: disruption of cognitive functions such as learning and memory
- cardiovascular system
- nervous system
- gastrointestinal
Evidence sourcelacrimation
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: lacrimation
- nervous system
- respiratory
- liver
- cardiovascular
- gastrointestinal
PubMed 28216264irritability
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: irritability
- nervous system
- respiratory
- liver
- cardiovascular
- gastrointestinal
PubMed 28216264decreased locomotor activity
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased locomotor activity
- nervous system
- respiratory
- liver
- cardiovascular
- gastrointestinal
PubMed 28216264cough
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: cough
- nervous system
- respiratory
- liver
- cardiovascular
- gastrointestinal
PubMed 28216264increased salivation
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased salivation
- nervous system
- respiratory
- liver
- cardiovascular
- gastrointestinal
PubMed 28216264muscle cramps
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: muscle cramps
- nervous system
- respiratory
- liver
- cardiovascular
- gastrointestinal
PubMed 28216264
And 14 more, listed on the interactive page.
proconvulsant
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: proconvulsant
- cardiovascular system
- central nervous system
- gastrointestinal
PubMed 23197038decreased gastric acid secretion
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: decreased gastric acid secretion
- cardiovascular system
- central nervous system
- gastrointestinal
PubMed 23197038hyperthermia
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: hyperthermia
- cardiovascular system
- central nervous system
- gastrointestinal
PubMed 23197038blurred vision
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: blurred vision
- cardiovascular system
- central nervous system
- gastrointestinal
PubMed 23197038receptor binding
Studies
- biochemical: NVS_GPCR_hM1, is one of one assay component(s) measured or calculated from the NVS_GPCR_hM1 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.
Biological samples
- cell-free
Evidence sourceincreased gastric acid secretion
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: increased gastric acid secretion
- cardiovascular system
- central nervous system
- gastrointestinal
PubMed 23197038tachycardia
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: tachycardia
- cardiovascular system
- central nervous system
- gastrointestinal
PubMed 23197038decreased cognitive function
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: decreased cognitive function
- cardiovascular system
- central nervous system
- gastrointestinal
PubMed 23197038hypertension
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: hypertension
- cardiovascular system
- central nervous system
- gastrointestinal
PubMed 23197038
Related records
Trials (617)
- "Death Rattle" - A Double Blind, Randomly Controlled, Crossover Trial
- "Low Dose Sugammadex Combined With Neostigmine and Glycopyrrolate Versus Full Dose Sugammadex for Reversal of Rocuronium-induced Neuromuscular Blockade: a Cost Saving Strategy"
- 0.6 vs. 1.2 mg Atropine Together With Neostigmine 2.5 mg on Heart Rate in Patient Receiving Muscle Relaxant
- 1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD)
- 4FMFES-PET Imaging of Endometrial and Ovarian Cancers
- A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.
- A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium 62.5 Microgram (mcg) Compared With Glycopyrronium 44 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
- A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation
- A 16-Week Study of Pirenzepine or Placebo to Treat HIV-Associated Distal Sensory Polyneuropathy in Patients With HIV
- A 24-Week Study of Topical Pirenzepine or Placebo in Type 2 Diabetic Patients (T2DM) With Peripheral Neuropathy
- A 6-week Dose Ranging Study of CHF 5259 pMDI in Subjects With Chronic Obstructive Pulmonary Disease
- A Clinical Study of Gimatecan in Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
- A Comparative Bioavailability and Adhesion Performance Study, Comparing a New Scopolamine Transdermal Delivery System Formulation to the Currently Established Reference Transdermal Delivery System in Healthy Adult Participants.
- A Comparison Study of the Efficacy of Quetiapine and Haloperidol in Agitated Adults in Emergency Room
- A Confirmatory Safety and Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis
- A Dose Ascending, Study To Examine The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of GSK233705B.
- A Dose-Ranging Study of the Effect of Glycopyrrolate in Subjects With Axillary Hyperhidrosis
- A Double-blind Comparison of Scopolamine With Cinnarizin for Prevention of Simulator Sickness
- A Novel Usage of Transdermal Scopolamine in Reducing Narcotic Usage in Outpatient Hand Surgery
- A PET/MRI Study of Cobenfy on Dopamine Transmission in Schizophrenia
Drugs (67)
- Afacifenacin Muscarinic acetylcholine receptor antagonist
- Anisotropine Muscarinic acetylcholine receptor M1 antagonist
- Anisotropine methylbromide Muscarinic acetylcholine receptor M1 antagonist
- ASM-024 Muscarinic acetylcholine receptor M1 antagonist
- Atropine Muscarinic acetylcholine receptor M1 antagonist
- Atropine sulfate Muscarinic acetylcholine receptor M1 antagonist
- Benztropine Muscarinic acetylcholine receptor M1 antagonist
- Benztropine mesylate Muscarinic acetylcholine receptor M1 antagonist
- Biperiden Muscarinic acetylcholine receptor M1 antagonist
- Biperiden hydrochloride Muscarinic acetylcholine receptor M1 antagonist
- Biperiden lactate Muscarinic acetylcholine receptor M1 antagonist
- Cevimeline Muscarinic acetylcholine receptor M1 agonist
- Cevimeline hydrochloride Muscarinic acetylcholine receptor M1 agonist
- Clidinium Muscarinic acetylcholine receptor M1 antagonist
- Clidinium bromide Muscarinic acetylcholine receptor M1 antagonist
- Cycrimine Muscarinic acetylcholine receptor M1 antagonist
- Cycrimine hydrochloride Muscarinic acetylcholine receptor M1 antagonist
- Darotropium Muscarinic acetylcholine receptor antagonist
- Darotropium bromide Muscarinic acetylcholine receptor antagonist
- Dicyclomine Muscarinic acetylcholine receptor M1 antagonist